Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $18.4 Million - $19.4 Million
-127,073 Reduced 55.55%
101,674 $15.4 Million
Q2 2022

Aug 15, 2022

BUY
$83.14 - $145.99 $18.4 Million - $32.3 Million
221,116 Added 2897.6%
228,747 $33.3 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $4.77 Million - $6.2 Million
-43,376 Reduced 85.04%
7,631 $905,000
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $6.95 Million - $10.3 Million
-69,703 Reduced 57.74%
51,007 $7.03 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $7.18 Million - $10.1 Million
72,656 Added 151.2%
120,710 $16.8 Million
Q2 2021

Aug 16, 2021

SELL
$65.78 - $105.02 $5.94 Million - $9.48 Million
-90,281 Reduced 65.26%
48,054 $4.67 Million
Q1 2021

May 17, 2021

SELL
$64.07 - $91.75 $1.61 Million - $2.31 Million
-25,174 Reduced 15.4%
138,335 $9.46 Million
Q4 2020

Feb 16, 2021

SELL
$65.07 - $98.24 $1.07 Million - $1.61 Million
-16,388 Reduced 9.11%
163,509 $14 Million
Q3 2020

Nov 16, 2020

BUY
$59.04 - $77.95 $3.3 Million - $4.36 Million
55,957 Added 45.15%
179,897 $11.7 Million
Q2 2020

Aug 14, 2020

SELL
$29.01 - $74.23 $433,902 - $1.11 Million
-14,957 Reduced 10.77%
123,940 $9.06 Million
Q1 2020

May 15, 2020

BUY
$27.51 - $57.29 $72,406 - $150,787
2,632 Added 1.93%
138,897 $4.73 Million
Q4 2019

Feb 14, 2020

SELL
$40.86 - $57.65 $2.41 Million - $3.4 Million
-58,989 Reduced 30.21%
136,265 $7.42 Million
Q3 2019

Nov 14, 2019

SELL
$37.38 - $49.47 $1.56 Million - $2.06 Million
-41,662 Reduced 17.59%
195,254 $8.15 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $7.87 Million - $13.3 Million
197,879 Added 506.9%
236,916 $10.4 Million
Q1 2019

May 15, 2019

BUY
$34.52 - $53.29 $1.35 Million - $2.08 Million
39,037 New
39,037 $2.01 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.